Kazia Therapeutics (KZA) CEO, Dr James Garner discusses the progress of the company’s two drugs that are in development to treat brain & ovarian cancer.

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

CommSec's Tom Piotrowski speaks with Novogen Ltd (NRT) CEO & Executive Director, Dr James Garner about the company’s key milestones over the past 12 months and the clinical trials for its brain cancer treatment drug.

Novogen (ASX: NRT), Chief Executive Officer & Executive Director Dr James Garner , gives an update on Novogen since coming on board in 2016.

CommSec's Tom Piotrowski speaks with Kazia Therapeutics (KZA) CEO & Managing Director, Dr James Garner about the company’s recent name change from Novogen and progress of its ovarian cancer and brain cancer drug trials.

Novogen Sky News Interview